Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...
Metabolic dysfunction–associated steatohepatitis—MASH—is suddenly one of the buzziest sectors in the pharma industry again. Novo Nordisk paid $5.2 billion to get Akero Therapeutics in October, adding ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — European policymakers on Thursday unveiled a compromise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback